Oak Asset Management LLC Has $672,000 Stock Holdings in Pfizer Inc. (NYSE:PFE)

Oak Asset Management LLC raised its stake in Pfizer Inc. (NYSE:PFE) by 39.1% in the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 24,215 shares of the biopharmaceutical company’s stock after acquiring an additional 6,809 shares during the period. Oak Asset Management LLC’s holdings in Pfizer were worth $672,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in PFE. Advisor OS LLC raised its holdings in shares of Pfizer by 1.0% during the 4th quarter. Advisor OS LLC now owns 35,202 shares of the biopharmaceutical company’s stock worth $1,013,000 after buying an additional 365 shares in the last quarter. Safeguard Investment Advisory Group LLC raised its holdings in shares of Pfizer by 3.9% during the 4th quarter. Safeguard Investment Advisory Group LLC now owns 9,987 shares of the biopharmaceutical company’s stock worth $288,000 after buying an additional 371 shares in the last quarter. Lantz Financial LLC raised its holdings in shares of Pfizer by 1.3% during the 1st quarter. Lantz Financial LLC now owns 30,582 shares of the biopharmaceutical company’s stock worth $849,000 after buying an additional 381 shares in the last quarter. King Wealth Management Group raised its holdings in shares of Pfizer by 2.4% during the 4th quarter. King Wealth Management Group now owns 16,686 shares of the biopharmaceutical company’s stock worth $480,000 after buying an additional 388 shares in the last quarter. Finally, Advance Capital Management Inc. raised its holdings in shares of Pfizer by 4.0% during the 4th quarter. Advance Capital Management Inc. now owns 10,177 shares of the biopharmaceutical company’s stock worth $293,000 after buying an additional 391 shares in the last quarter. 68.36% of the stock is owned by institutional investors and hedge funds.

Pfizer Trading Up 0.6 %

NYSE PFE opened at $27.98 on Monday. The business’s 50-day moving average price is $27.90 and its two-hundred day moving average price is $27.69. Pfizer Inc. has a 12 month low of $25.20 and a 12 month high of $37.80. The firm has a market capitalization of $158.55 billion, a PE ratio of -466.26, a price-to-earnings-growth ratio of 1.10 and a beta of 0.69. The company has a current ratio of 1.05, a quick ratio of 0.78 and a debt-to-equity ratio of 0.66.

Pfizer (NYSE:PFE) last released its quarterly earnings results on Wednesday, May 1st. The biopharmaceutical company reported $0.82 EPS for the quarter, beating analysts’ consensus estimates of $0.56 by $0.26. Pfizer had a positive return on equity of 8.64% and a negative net margin of 0.56%. The firm had revenue of $14.88 billion for the quarter, compared to analyst estimates of $13.87 billion. During the same quarter in the previous year, the company posted $1.23 EPS. The business’s revenue was down 19.5% on a year-over-year basis. On average, analysts expect that Pfizer Inc. will post 2.38 EPS for the current year.

Pfizer Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, September 3rd. Investors of record on Friday, July 26th will be given a dividend of $0.42 per share. The ex-dividend date of this dividend is Thursday, July 25th. This represents a $1.68 annualized dividend and a dividend yield of 6.00%. Pfizer’s payout ratio is -2,799.53%.

Wall Street Analyst Weigh In

PFE has been the subject of a number of research analyst reports. Morgan Stanley boosted their price target on Pfizer from $28.00 to $29.00 and gave the stock an “equal weight” rating in a report on Thursday, May 2nd. Cantor Fitzgerald reissued an “overweight” rating and set a $45.00 price target on shares of Pfizer in a report on Wednesday, June 26th. BMO Capital Markets restated an “outperform” rating and set a $36.00 price objective (up previously from $33.00) on shares of Pfizer in a research report on Thursday, May 2nd. Finally, Argus lowered Pfizer from a “buy” rating to a “hold” rating in a research report on Friday, March 22nd. Nine investment analysts have rated the stock with a hold rating and six have issued a buy rating to the company’s stock. Based on data from MarketBeat, Pfizer presently has an average rating of “Hold” and an average price target of $35.54.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.